TransCode Therapeutics Inc’s Increase Of 45.13% Makes It Worthwhile To Consider Again

TransCode Therapeutics Inc (NASDAQ:RNAZ) price on Wednesday, February 05, rose 45.13% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $8.94.

A look at the stock’s price movement, the close in the last trading session was $6.16, moving within a range at $6.5701 and $12.7. The beta value (5-Year monthly) was 0.647. Turning to its 52-week performance, $66.33 and $2.66 were the 52-week high and 52-week low respectively. Overall, RNAZ moved 145.60% over the past month.

TransCode Therapeutics Inc’s market cap currently stands at around $6.23 million, with investors looking forward to this quarter’s earnings report slated for in March.

Analysts have a consensus estimate of 300k for the company’s revenue for the quarter, with a low and high estimate of 300k and 300k respectively.

Turning to the stock’s technical picture we see that short term indicators suggest on average that RNAZ is a 50% Sell. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.

RNAZ’s current price about 63.02% and 39.00% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 62.12, while 7-day volatility ratio is 38.27% and 40.15% in the 30-day chart. Further, TransCode Therapeutics Inc (RNAZ) has a beta value of 1.02, and an average true range (ATR) of 2.36.

If we refocus on TransCode Therapeutics Inc (NASDAQ:RNAZ), historical trading data shows that trading volumes averaged 6.58 over the past 10 days and 1.14 million over the past 3 months. The company’s latest data on shares outstanding shows there are 0.70 million shares.

The 0.12% of TransCode Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 23.92% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 0.74 million on 2024-10-31, giving us a short ratio of 0.5. The data shows that as of 2024-10-31 short interest in TransCode Therapeutics Inc (RNAZ) stood at 430.99999999999994 of shares outstanding, with shares short falling to 1.38 million registered in 2024-09-30. Current price change has pushed the stock 165.28% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the RNAZ stock continues to rise going into the next quarter.

Most Popular